AI-generated summary
The authors report a study of 31 patients with medication-related osteonecrosis of the jaw treated with diode laser photobiomodulation alongside antibiotics, with follow-up at 3 and 6 months. They report that none of 14 patients with stage I disease showed signs or symptoms during 3 months of follow-up, while in stage II and III cases photobiomodulation eased symptoms but still needed surgery.
- Participants
- 31
- Who or what was studied
- 31 patients with medication-related osteonecrosis of the jaw: 14 with stage I and 17 with stage II or III; 10 had osteoporosis and 21 had cancer treatment
- Wavelengths
- 635 nm
- Limits stated in the abstract
- The abstract describes no control group, the study is small, and the sole variable reported is disease stage, with all patients receiving the same procedure alongside antibiotics.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background/Objectives
The development of pharmacotherapy, particularly in antiangiogenic drugs, has led to the emergence of MRONJ as a significant side effect. With the increasing incidence of cancer, the management of MRONJ poses a growing challenge for clinicians. The aim of the study is to evaluate the effectiveness of photobiomodulation (PBM) in treating patients with stage I, II, and III medication-related osteonecrosis of the jaw (MRONJ).
Methods
A total of 31
Patients Were Divided Into Two Groups
Group 1 (n = 14 patients), with Stage 1 MRONJ; and Group 2 (n = 17 patients), with Stage II and III MRONJ. In total, 10 patients had osteoporosis and 21 underwent cancer treatment. The sole variable under investigation was the stage of MRONJ, as all patients underwent the same photobiomodulation (PBM) procedure. For treatment protocol, PBM with a diode laser was used (Lasotronix Smart M Pro, Piaseczno, Poland) with the following parameters: 100 mW; continuous wave; 635 nm; 4 J/cm2 for 20 s; irradiance for one point: 0.398 W/cm2; fluency for one point: 7.96 J/cm2, and for four points, which was one appointment: 31.83 J/cm2; and tip diameter 8 mm (three points from buccal surface, perpendicular for the lesion and one point on the floor of the mouth) during each session. The protocol assumed 10 sessions at 3 days intervals. Antibiotic therapy (amoxicillin with clavulanic acid 875 mg + 125 mg or clindamycin 600 mg every 12 h) was started 3 days before PBM and continued for 14 days. Antibiotics were taken for 14 days in total. Pain was measured with VAS scale. Follow-up was after 3 and 6 months.
Results
Among the 14 patients in Group 1, none exhibited any clinical signs or symptoms of MRONJ during the 3 months follow-up, and complete cure was achieved. While PBM resolved inflammation and pain in stage II MRONJ, further surgical intervention was necessary to fully address the condition.
Conclusions
PBM is an effective treatment for achieving complete recovery in patients with Stage 1 MRONJ. However, in Stages II and III MRONJ, PBM significantly alleviates symptoms but requires complementary surgical intervention to achieve full resolution. A beneficial aspect is the reduction in pain symptoms and the extent of surgical intervention.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 635 nm
- Energy density (fluence)
- 4 J/cm2, 7.96 J/cm2, 31.83 J/cm2
- Power
- 100 mW
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Visual analogue scale, Light-emitting diode, Inflammation, Irradiance, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.